End-of-Life Care: Guidelines for Patient-Centered Communication

When patients are diagnosed with cancer, primary care physicians often must deliver the bad news, discuss the prognosis, and make appropriate referrals. When delivering bad news, it is important to prioritize the key points that the patient should retain. Physicians should assess the patient’s emotional state, readiness to engage in the discussion, and level of understanding about the condition. The discussion should be tailored according to these assessments. Often, multiple visits are needed. When discussing prognosis, physicians should be sensitive to variations in how much information patients want to know. The challenge for physicians is to communicate prognosis accurately without giving false hope. All physicians involved in the patient’s care should coordinate their key prognosis points to avoid giving the patient mixed messages. As the disease progresses, physicians must reassess treatment effectiveness and discuss the values, goals, and preferences of the patient and family. It is important to initiate conversations about palliative care early in the disease course when the patient is still feeling well. There are innovative hospice programs that allow for simultaneous curative and palliative care. When physicians discuss the transition from curative to palliative care, they should avoid phrases that may convey to the patient a sense of failure or abandonment. Physicians also must be cognizant of how cultural factors may affect end-of-life discussions. Sensitivity to a patient’s cultural and individual preferences will help the physician avoid stereotyping and making incorrect assumptions. (Am Fam Physician. 2008;77(2):167-174. Copyright © 2008 American Academy of Family Physicians.)

New England Journal of Medicine. Vol. 357. Núm. 22


McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M et al for the TPL102357 Study Group Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C. Págs. 2227-2236 R TC (s) PDF (s) 

Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B et alEltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura. Págs. 2237-2247 R TC (s) PDF (s) 

Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JGF, Cornel JH et al for the CORONA GroupRosuvastatin in Older Patients with Systolic Heart Failure. Págs. 2248-2261 R TC (s) PDF (s) 

Handke M, Harloff A, Olschewski M, Hetzel A, Geibel APatent Foramen Ovale and Cryptogenic Stroke in Older Patients. Págs. 2262-2268 R TC (s) PDF (s) 


Schwartz RS Immune Thrombocytopenic Purpura — From Agony to Agonist. Págs. 2299-2301 TC (s) PDF (s) 

Masoudi FAStatins for Ischemic Systolic Heart Failure. Págs. 2301-2304 TC (s) PDF (s) 


J. Unützer Late-Life Depression. Págs. 2269-2276 TC (s) PDF (s) 

Brenner DJ, Hall EJComputed Tomography — An Increasing Source of Radiation Exposure. Págs. 2277-2284 TC PDF